VIVANI MEDICAL INC (VANI) Stock News

USA - Nasdaq - NASDAQ:VANI - US92854B1098 - Common Stock

1.32 USD

0 (0%)

Last: 11/26/2025, 10:33:39 AM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

VANI Latest News, Press Relases and Analysis

All

Press Releases

13 days ago - By: Vivani Medical, Inc.

Vivani Medical Provides Business Update and Reports Third Quarter 2025 Financial Results

a month ago - By: Vivani Medical, Inc.

Vivani Medical, Inc. Announces Closing of Common Stock Offering

a month ago - By: Vivani Medical, Inc.

Vivani Medical, Inc. Announces Pricing of Common Stock Offering

a month ago - By: Vivani Medical, Inc.

Vivani Medical to Present at the ThinkEquity Conference on October 30, 2025

2 months ago - By: Vivani Medical, Inc.

Vivani Medical Withdraws Record Date for Cortigent Neuromodulation Subsidiary Spin-Off

2 months ago - By: Vivani Medical, Inc.

Vivani Medical to Present at the Emerging Growth Conference on September 25, 2025

2 months ago - By: Benzinga - Mentions: USBC CURX CODX ENVB ...

12 Health Care Stocks Moving In Wednesday's Intraday Session

2 months ago - By: Vivani Medical, Inc.

Vivani Medical Announces Record Date for Spin-off of Cortigent Neuromodulation Subsidiary to Shareholders

2 months ago - By: Benzinga - Mentions: APRE CODX RNAZ ISPC ...

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

3 months ago - By: Vivani Medical, Inc.

Vivani Medical Provides Update on Clinical Development Plans for NPM-139 Semaglutide Implant for Chronic Weight Management

3 months ago - By: Vivani Medical, Inc.

Vivani Medical CEO Adam Mendelsohn to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025

3 months ago - By: Vivani Medical, Inc.

Vivani Medical Provides Business Update Including $10M Equity Financing and Reports Second Quarter 2025 Financial Results

4 months ago - By: Vivani Medical, Inc.

Vivani Medical Announces Rapid Advancement of NPM-139, a Novel Semaglutide Implant, Following Positive Weight Loss Data from an Ongoing Preclinical Study of NPM-139 and Promising Results from the LIBERATE-1 Phase 1 Clinical Study of NPM-115

6 months ago - By: Zacks Investment Research - Mentions: ANGO CVS ITGR

Vivani Stock Gains After Announcing Spin-Off Plans for Cortigent Unit

6 months ago - By: Vivani Medical, Inc.

Vivani Medical Announces Filing of Form 10 Registration Statement for Planned Spin-Off of Cortigent Neurostimulation Business to Vivani Shareholders

7 months ago - By: Vivani Medical, Inc.

Vivani Medical Provides Business Update Including $3M Equity Financing and Reports First Quarter 2025 Financial Results

7 months ago - By: Vivani Medical, Inc.

Vivani Medical to Present at the American Association of Pharmaceutical Scientists’ “Beyond GLP1s: Where the Science will Take Business Next” Virtual Workshop

7 months ago - By: Vivani Medical, Inc.

Vivani Medical to Participate in Virtual Fireside Chat Hosted by H.C. Wainwright & Company

8 months ago - By: Vivani Medical, Inc.

Vivani Medical and Okava Expand Collaboration to Develop OKV-119 for Dogs, Targeting Metabolic Health and Longevity

8 months ago - By: Yahoo Finance - Mentions: CMCO CHWY KR HON ...

Do You Believe in Columbus McKinnon Corp.’s (CMCO) Compelling Risk/Reward Opportunity?

8 months ago - By: Vivani Medical, Inc.

Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

8 months ago - By: Vivani Medical, Inc.

Vivani Medical Announces $8.25M Private Placement Equity Financing

8 months ago - By: Stocktwits - Mentions: VTI VXF

Vivani Medical Announces Promising Preclinical Weight Loss Data For Its Semaglutide Implant: Retail Sentiment Soars

8 months ago - By: Vivani Medical, Inc.

Vivani Medical Announces Positive Preclinical Weight Loss Data for NPM-139 Semaglutide Implant, with Potential for Once-Yearly Dosing

8 months ago - By: Vivani Medical, Inc.

Vivani Medical to Present at the Emerging Growth Conference on March 27, 2025

9 months ago - By: Vivani Medical, Inc.

Vivani Medical Achieves First Implant and Full Enrollment in the First-in-Human Clinical Trial of GLP-1 Implant NPM-115 in Obese or Overweight Adults

9 months ago - By: Vivani Medical, Inc.

Vivani Medical Announces Intent to Spin Off Cortigent Neurostimulation Business

a year ago - By: Vivani Medical, Inc.

Vivani Medical Announces Initiation of First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia

a year ago - By: Vivani Medical, Inc.

Vivani Medical to Present at the Innovation in Obesity Therapeutics Summit West Coast

a year ago - By: Vivani Medical, Inc.

Vivani Medical Provides Business Update Including $5M Equity Financing and Reports Third Quarter 2024 Financial Results